NASDAQ:CHEK Check-Cap (CHEK) Stock Forecast, Price & News $1.81 +0.03 (+1.69%) (As of 06/5/2023 ET) Add Compare Share Share Today's Range$1.80▼$1.8950-Day Range$1.30▼$1.8452-Week Range$1.22▼$9.20Volume30,678 shsAverage Volume61,093 shsMarket Capitalization$8.72 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Check-Cap MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside286.7% Upside$7.00 Price TargetShort InterestHealthy0.87% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.80) to ($1.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.69 out of 5 stars 3.3 Analyst's Opinion Consensus RatingCheck-Cap has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, Check-Cap has a forecasted upside of 286.7% from its current price of $1.81.Amount of Analyst CoverageCheck-Cap has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.87% of the float of Check-Cap has been sold short.Short Interest Ratio / Days to CoverCheck-Cap has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Check-Cap has recently increased by 226.28%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCheck-Cap does not currently pay a dividend.Dividend GrowthCheck-Cap does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CHEK. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Check-Cap this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for CHEK on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Check-Cap to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Check-Cap insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.48% of the stock of Check-Cap is held by insiders.Percentage Held by InstitutionsOnly 17.59% of the stock of Check-Cap is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Check-Cap are expected to grow in the coming year, from ($1.80) to ($1.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Check-Cap is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Check-Cap is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCheck-Cap has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Check-Cap (NASDAQ:CHEK) StockCheck-Cap Ltd. is a clinical stage medical diagnostics company, which engages in the development of ingestible imaging capsule system for colorectal cancer screening. Its patented technology, C-Scan, is a patient-friendly preparation-free test designed to detect polyps before they may transform into cancer. The company was founded by Yoav Kimchy in 2005 and is headquartered in Isfiya, Israel.Read More Receive CHEK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Check-Cap and its competitors with MarketBeat's FREE daily newsletter. Email Address CHEK Stock News HeadlinesJune 5, 2023 | americanbankingnews.comCheck-Cap (NASDAQ:CHEK) Now Covered by StockNews.comJune 1, 2023 | sg.finance.yahoo.comCHEK - Check-Cap Ltd.June 5, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 27, 2023 | americanbankingnews.comCheck-Cap (NASDAQ:CHEK) Now Covered by Analysts at StockNews.comMay 20, 2023 | americanbankingnews.comCheck-Cap Ltd. Expected to Post Q2 2023 Earnings of ($0.53) Per Share (NASDAQ:CHEK)May 18, 2023 | americanbankingnews.comCheck-Cap (NASDAQ:CHEK) Coverage Initiated by Analysts at StockNews.comMay 15, 2023 | msn.comHC Wainwright & Co. Reiterates Check-Cap (CHEK) Buy RecommendationMay 15, 2023 | markets.businessinsider.comCheck-Cap (CHEK) Gets a Buy from H.C. WainwrightJune 5, 2023 | Vantage Point (Ad)Instantly Find Hidden Trade OpportunitiesThere’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market. May 12, 2023 | finanznachrichten.deCheck-Cap Ltd.: Check-Cap Reports First Quarter 2023 Financial ResultsMay 11, 2023 | seekingalpha.comCheck-Cap GAAP EPS of -$0.76 misses by $0.02May 11, 2023 | finance.yahoo.comCheck-Cap Reports First Quarter 2023 Financial ResultsMay 10, 2023 | americanbankingnews.comCheck-Cap (NASDAQ:CHEK) Stock Crosses Below Fifty Day Moving Average of $1.86April 26, 2023 | americanbankingnews.comCheck-Cap (NASDAQ:CHEK) Earns Sell Rating from Analysts at StockNews.comApril 18, 2023 | americanbankingnews.comCheck-Cap (NASDAQ:CHEK) Coverage Initiated at StockNews.comApril 17, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Check-Cap (NASDAQ:CHEK)April 9, 2023 | americanbankingnews.comCheck-Cap (NASDAQ:CHEK) Receives New Coverage from Analysts at StockNews.comApril 8, 2023 | americanbankingnews.comCheck-Cap (NASDAQ:CHEK) Price Target Lowered to $7.00 at HC WainwrightMarch 31, 2023 | finance.yahoo.comCheck-Cap Reports Fourth Quarter and Full Year 2022 Financial ResultsMarch 21, 2023 | finance.yahoo.comCheck-Cap Issues an Update to ShareholdersMarch 21, 2023 | finance.yahoo.comWhy Are Check-Cap Shares Plummeting Today?November 30, 2022 | finance.yahoo.comCheck-Cap Reports Third Quarter 2022 Financial Results and Provides a Corporate UpdateOctober 20, 2022 | bbc.comFact-checking Liz Truss at PMQs - BBCOctober 20, 2022 | bloomberg.comGermany's Scholz Warns EU Gas-Price Cap Could Crimp Supplies - BloombergOctober 19, 2022 | globenewswire.comGlobal Smart Pills Market size to record 11.4% CAGR through 2028 - GlobeNewswireOctober 18, 2022 | cnbc.comHere's what you need to know about 2023 Medicare prescription drug plans during open enrollment - CNBCOctober 18, 2022 | bloomberg.comRussia Won't Sell Price-Capped Crude. Period - BloombergSee More Headlines CHEK Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CHEK Company Calendar Last Earnings3/31/2023Today6/05/2023Next Earnings (Estimated)8/30/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry X - ray apparatus & tubes Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CHEK CUSIPN/A CIK1610590 Webwww.check-cap.com Phone972546706451Fax972-4821-1267Employees65Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.00 High Stock Price Forecast$7.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+283.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,110,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-41.04% Return on Assets-37.21% Debt Debt-to-Equity RatioN/A Current Ratio10.80 Quick Ratio10.80 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.57 per share Price / Book0.21Miscellaneous Outstanding Shares4,820,000Free Float4,798,000Market Cap$8.80 million OptionableNot Optionable BetaN/A Key ExecutivesAlex OvadiaChief Executive OfficerJoshua BelkarVice President-OperationsMira RosenzweigChief Financial OfficerYoav KimchyChief Technology OfficerBoaz ShpigelmanVice President-Research & DevelopmentKey CompetitorsExicureNASDAQ:XCURSurgalignNASDAQ:SRGASeaStar MedicalNASDAQ:ICUAethlon MedicalNASDAQ:AEMDBellicum PharmaceuticalsNASDAQ:BLCMView All CompetitorsInstitutional OwnershipSabby Management LLCBought 63,346 shares on 5/16/2023Ownership: 1.314%Susquehanna International Group LLPBought 39,927 shares on 5/16/2023Ownership: 0.828%View All Institutional Transactions CHEK Stock - Frequently Asked Questions Should I buy or sell Check-Cap stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Check-Cap in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CHEK shares. View CHEK analyst ratings or view top-rated stocks. What is Check-Cap's stock price forecast for 2023? 2 brokerages have issued 12 month price objectives for Check-Cap's stock. Their CHEK share price forecasts range from $7.00 to $7.00. On average, they expect the company's share price to reach $7.00 in the next year. This suggests a possible upside of 283.6% from the stock's current price. View analysts price targets for CHEK or view top-rated stocks among Wall Street analysts. How have CHEK shares performed in 2023? Check-Cap's stock was trading at $2.20 at the beginning of the year. Since then, CHEK stock has decreased by 17.1% and is now trading at $1.8248. View the best growth stocks for 2023 here. Are investors shorting Check-Cap? Check-Cap saw a increase in short interest in May. As of May 15th, there was short interest totaling 50,900 shares, an increase of 226.3% from the April 30th total of 15,600 shares. Based on an average daily trading volume, of 63,400 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.9% of the company's stock are sold short. View Check-Cap's Short Interest. When is Check-Cap's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 30th 2023. View our CHEK earnings forecast. How were Check-Cap's earnings last quarter? Check-Cap Ltd. (NASDAQ:CHEK) released its quarterly earnings results on Friday, March, 31st. The medical research company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.04. When did Check-Cap's stock split? Check-Cap shares reverse split before market open on Friday, November 25th 2022. The 1-20 reverse split was announced on Friday, November 25th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Check-Cap own? Based on aggregate information from My MarketBeat watchlists, some companies that other Check-Cap investors own include Alibaba Group (BABA), Navios Maritime Partners (NMM), New Residential Investment (NRZ), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Acasti Pharma (ACST), Avinger (AVGR), Biocept (BIOC) and Purple Biotech (KTOV). When did Check-Cap IPO? (CHEK) raised $13 million in an initial public offering on Thursday, February 19th 2015. The company issued 1,200,000 shares at $10.00-$12.00 per share. Chardan Capital Markets and Maxim Group served as the underwriters for the IPO and Feltl and Company was co-manager. What is Check-Cap's stock symbol? Check-Cap trades on the NASDAQ under the ticker symbol "CHEK." Who are Check-Cap's major shareholders? Check-Cap's stock is owned by a variety of institutional and retail investors. Top institutional investors include Sabby Management LLC (1.31%) and Susquehanna International Group LLP (0.83%). How do I buy shares of Check-Cap? Shares of CHEK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Check-Cap's stock price today? One share of CHEK stock can currently be purchased for approximately $1.82. How much money does Check-Cap make? Check-Cap (NASDAQ:CHEK) has a market capitalization of $8.80 million. The medical research company earns $-19,110,000.00 in net income (profit) each year or ($2.24) on an earnings per share basis. How can I contact Check-Cap? Check-Cap's mailing address is 29 ABBA HUSHI AVE. P.O.BOX 1271, ISFIYA L3, 3009000. The official website for the company is www.check-cap.com. The medical research company can be reached via phone at 972546706451, via email at jeremy@lifesciadvisors.com, or via fax at 972-4821-1267. This page (NASDAQ:CHEK) was last updated on 6/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Check-Cap Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.